T1	Premise 1598 1765	At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.
T2	Premise 1766 1953	The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).
T3	Premise 1954 2071	The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.
T4	Claim 2094 2229	the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.
T5	Claim 2245 2371	this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;
T6	MajorClaim 2471 2542	this regimen could not be recommended for a phase III randomized study.
R1	Support Arg1:T5 Arg2:T6	
R2	Support Arg1:T3 Arg2:T5	
R3	Support Arg1:T1 Arg2:T5	
R4	Support Arg1:T2 Arg2:T5	
